FoxP3 mRNA transcripts and regulatory cells in renal transplant recipients 10 years after donor marrow infusion

Transplantation

Volumn 83, Issue 12, 2007, Pages 1611-1619

  Cirocco, Robert E ^a,b   Carreño, Manuel R ^a   Mathew, James M ^a   Garcia Morales, Rolando O ^a   Fuller, Laphalle ^a,b   Esquenazi, Violet ^a,b,c   Ciancio, Gaetano ^a   Burke, George W ^a   Gaynor, Jeffrey J ^a   Blomberg, Bonnie B ^b   Rosen, Anne ^a   Kleiner, Gary ^b   Ricordi, Camillo ^a,b   Miller, Joshua ^a,b,c  

^a Florida   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Bone marrow; FoxP3; Regulatory cells; Renal transplantation

Indexed keywords

CD3 ANTIGEN; MESSENGER RNA; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; BONE MARROW; CD4+ CD25+ T LYMPHOCYTE; CHIMERA; CONTROLLED STUDY; CORRELATION ANALYSIS; EX VIVO STUDY; FLOW CYTOMETRY; GENETIC TRANSCRIPTION; GRAFT FAILURE; HUMAN; HUMAN CELL; HUMAN TISSUE; ILIAC CREST; IMMUNOREGULATION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; STATISTICAL SIGNIFICANCE;

ANTIGENS, CD3; BONE MARROW; BONE MARROW TRANSPLANTATION; FLOW CYTOMETRY; FOLLOW-UP STUDIES; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOPHENOTYPING; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; RNA, MESSENGER; T-LYMPHOCYTES; TRANSCRIPTION, GENETIC;

EID: 34250812497     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000266908.37446.02     Document Type: Article

References (45)

1. Ciancio G, Miller J, Garcia-Morales RO, et al. Six-year clinical effect of donor bone marrow infusions in renal transplant patients. Transplantation 2001; 71: 827.
2. Mathew JM, Garcia-Morales R, Fuller L, et al. Donor bone marrow-derived chimeric cells present in renal transplant recipients infused with donor marrow. I. Potent regulators of recipient antidonor immune responses. Transplantation 2000; 70: 1675.
3. Mathew JM, Miller J. Immunoregulatory role of chimerism in clinical organ transplantation. Bone Marrow Transplant 2001; 28: 115.
4. Mathew JM, Garcia-Morales RO, Carreno M, et al. Immune responses and their regulation by donor bone marrow cells in clinical organ transplantation. Transplant Immunol 2003; 11: 307.
5. Fudaba Y, Spitzer TR, Shaffer J, et al. Myeloma responses and tolerance following combined kidney and non-myeloablative marrow transplantation: In vivo and in vitro analyses. Am J Transplant 2006; 6: 2121.
6. Millan MT, Shizuru JA, Hoffmann P, et al. Mixed chimerism and immunosuppressive drug with-drawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation 2002; 73: 1386.
7. Barber WH, Mankin JA, Laskow DA, et al. Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients. Transplantation 1991; 51: 70.
8. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3: 199.
9. Yamazaki S, Inaba K, Tarbell KV, Steinman RM. Dendritic cells expand antigen-specific Foxp3CD25CD4 regulatory T cells including suppressors of alloreactivity. Immunol Rev 2006; 212: 314.
10. Floege J. Recurrent IgA nephropathy after renal transplantation. Semin Nephrol 2004; 24: 287.
11. Korbet SM. Treatment of primary focal segmental glomerulosclerosis. Kidney Int 2002; 62: 2301.
12. Moroni G, Tantardini F, Gallelli B, et al. The long-term prognosis of renal transplantation in patients with lupus nephritis. Am J Kidney Dis 2005; 45: 903.
13. Shevach EM, DiPaolo RA, Andersson J, et al. The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells. Immunol Rev 2006; 212: 60.
14. Coffer PJ, Burgering BM. Forkhead-box transcription factors and their role in the immune system. Nat Rev Immunol 2004; 4: 889.
15. Taams LS, Smith J, Rustin MH, et al. Human anergic/suppressive CD4(+)CD25(+) T cells: A highly differentiated and apoptosis-prone population. Euro J Immunol 2001; 31: 1122.
16. + T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001; 193: 1295.
17. Nagler-Anderson C, Bhan AK, Podolsky DK, Terhorst C. Control freaks: Immune regulatory cells. Nature Immunol 2004; 5: 119.
18. Scotto L, Naiyer AJ, Galluzzo S, et al. Overlap between molecular markers expressed by naturally occurring CD4+CD25+ regulatory T cells and antigen specific CD4+CD25+ and CD8+CD28- T suppressor cells. Hum Immunol 2004; 65: 1297.
19. Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4(+) T reg cells. J Exp Med 2006; 203: 1701.
20. Watanabe N, Wang YH, Lee HK, et al. Hassall's corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus. Nature 2005; 436: 1181.
21. + precursors. J Immunol 2005; 175: 6107.
22. + Tregs and immune control. J Clin Invest 2004; 114: 1209.
23. Mazariegos GV, Zahorchak AF, Reyes J, et al. Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression. Am J Transplant 2005; 5: 314.
24. Muthukumar T, Dadhania D, Ding R, et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005; 353: 2342.
25. Strom TB. Rejection-more than the eye can see. N Engl J Med 2005; 353: 2394.
26. Bach FH, Auchincloss H. Transplantation Immunology. New York, NY: Wiley-Liss, 1995: 201.
27. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized trial of three renal transplant induction antibodies: Early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005; 80: 457.
28. Garcia-Morales R, Carreno M, Mathew J, et al. The effects of chimeric cells following donor bone marrow infusions as detected by PCR-flow assays in kidney transplant recipients. J Clin Invest 1997; 99: 1118.
29. Garcia-Morales R, Carreno M, Mathew J, et al. Continuing observations on the regulatory effects of donor-specific bone marrow cell infusions and chimerism in kidney transplant recipients. Transplantation 1998; 65: 956.
30. Garcia-Morales R, Esquenazi V, Zucker K, et al. An assessment of the effects of cadaver donor bone marrow on kidney allograft recipient blood cell chimerism by a novel technique combining PCR and flow cytometry. Transplantation 1996; 62: 1149.
31. Carreno MR, Fuller L, Mathew JM, et al. Human donor bone marrow cells induce in vitro "suppressor T cells" that functionally suppress autologous B cells. Human Immunol 2003; 64: 21.
32. Mathew JM, Fuller L, Carreno M, et al. Involvement of multiple subpopulations of human bone marrow cells in the regulation of allogeneic cellular immune responses. Transplantation 2000; 70: 1752.
33. Ciancio G, Burke GW, Gaynor JJ, et al. The use of Campath-1H as induction therapy in renal transplantation: Preliminary results. Transplantation 2004; 78: 426.
34. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: Research0034.1.
35. + regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res 2004; 64: 8451.
36. Lowsky R, Takahashi T, Liu YP, et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med 2005; 353: 1321.
37. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graftversus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196: 389.
38. Ermann J, Hoffmann P, Edinger M, et al. Only the CD62L + subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood 2005; 105: 2220.
39. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/ sirolimus in renal transplantation: Three-year analysis. Transplantation 2006; 81: 845.
40. Velthuis JH, Mol WM, Weimar W, Baan CC. CD4+CD25bright+ regulatory T cells can mediate donor nonreactivity in long-term immunosuppressed kidney allograft patients. Am J Transplant 2006; 6: 2955.
41. Barber WH, Diethelm AG, Laskow DA, et al. Use of cryopreserved donor bone marrow in cadaver kidney allograft recipients. Transplantation 1989; 47: 66.
42. Louis S, Braudeau C, Giral M, et al. Contrasting CD25hiCD4+T cells/ FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation 2006; 81: 398.
43. Miller J, Mathew J, Garcia-Morales R, et al. The human bone marrow as an immunoregulatory organ. Transplantation 1999; 68: 1079.
44. Warrington AJ, Corbisier P, Feilotter H, et al. Use of external RNA controls in gene expression assays, approved guidelines. Clinical Laboratory Standards Institute (NCCLS) 2006; 26: 7.
45. Miller J, Mathew JM, Esquenazi V. Toward tolerance to human organ transplants: A few additional corollaries and questions. Transplantation 2004; 77: 940.